Literature DB >> 24845702

Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation.

Wataru Yamamoto1, Eriko Ogusa, Kenji Matsumoto, Atsuo Maruta, Yoshiaki Ishigatsubo, Heiwa Kanamori.   

Abstract

Reduced-intensity conditioning allogeneic stem cell transplantation (RIC allo-SCT) is associated with less toxicity and is used for older patients. We retrospectively studied the predictive value of two risk assessment scores, which were the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and the pre-transplantation assessment of mortality (PAM) score, for assessing the outcome of RIC allo-SCT. Seventy-eight patients underwent transplantation between 2005 and 2013 at a single institution. RIC was performed with fludarabine and melphalan with/without total body irradiation. The 3-year overall survival of patients with an HCT-CI >3 was significantly worse than that of patients with an HCT-CI 0-3 (31.6% vs. 59.6%, P = 0.020). Also, the 3-year overall survival of patients with a PAM score >24 was significantly worse than that of those with a PAM score ≤24 (29.2% vs. 61.4%, P = 0.005). The present findings suggest that changing the cut-off values of these risk assessment scores can improve prediction of outcomes in patients receiving RIC allo-SCT with this conditioning regimen and we need validation by large-scale study with other regimens.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24845702     DOI: 10.1002/ajh.23764

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  2 in total

1.  External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.

Authors:  Roni Shouval; Joshua A Fein; Aniela Shouval; Ivetta Danylesko; Noga Shem-Tov; Maya Zlotnik; Ronit Yerushalmi; Avichai Shimoni; Arnon Nagler
Journal:  Blood Adv       Date:  2019-06-25

Review 2.  How I treat acute myeloid leukemia presenting with preexisting comorbidities.

Authors:  Yishai Ofran; Martin S Tallman; Jacob M Rowe
Journal:  Blood       Date:  2016-05-27       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.